BridgeBio Pharma Overview
- Year Founded
-
2015
- Status
-
Public
- Employees
-
730
- Stock Symbol
-
BBIO
- Investments
-
13
- Share Price
-
$45.98
- (As of Wednesday Closing)
BridgeBio Pharma General Information
Description
BridgeBio Pharma is a biotechnology company focused on discovering, developing, testing, and delivering transformative treatments for patients with genetic diseases. The company has four programs in its late-stage pipeline focusing on Mendelian disorders, oncology, and gene therapy. One of its key programs, Attruby (acoramidis) , is an orally administered small molecule designed to stabilize tetrameric transthyretin for the treatment of transthyretin amyloid cardiomyopathy.
Contact Information
Website
www.bridgebio.comCorporate Office
- 3160 Porter Drive
- Suite 250
- Palo Alto, CA 94304
- United States
Corporate Office
- 3160 Porter Drive
- Suite 250
- Palo Alto, CA 94304
- United States
BridgeBio Pharma Timeline
BridgeBio Pharma Stock Performance
As of 09-Jul-2025, BridgeBio Pharma’s stock price is $45.98. Its current market cap is $8.73B with 190M shares.
(As of Wednesday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $45.98 | $43.19 | $21.72 - $46.43 | $8.73B | 190M | 3.08M | -$3.53 |
BridgeBio Pharma Financials Summary
As of 31-Mar-2025, BridgeBio Pharma has a trailing 12-month revenue of $127M.
|
In Thousands, USD |
TTM 31-Mar-2025 | FY 2024 31-Dec-2024 | FY 2023 31-Dec-2023 | FY 2022 31-Dec-2022 |
|---|---|---|---|---|
| EV | 7,634,596 | 6,660,835 | 8,228,623 | 2,270,865 |
| Revenue | 127,415 | 221,902 | 9,303 | 77,648 |
| EBITDA | (570,478) | (454,078) | (583,506) | (404,985) |
| Net Income | (667,968) | (535,762) | (643,202) | (481,183) |
| Total Assets | 881,638 | 919,338 | 546,380 | 623,036 |
| Total Debt | 1,858,248 | 1,730,584 | 1,739,838 | 1,723,564 |
BridgeBio Pharma Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
BridgeBio Pharma Comparisons
Industry
Financing
Details
BridgeBio Pharma Competitors (94)
One of BridgeBio Pharma’s 94 competitors is IVERIC bio, a Formerly VC-backed company based in Parsippany, NJ.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| IVERIC bio | Formerly VC-backed | Parsippany, NJ | ||||
| Caribou Biosciences | Formerly VC-backed | Berkeley, CA | ||||
| Regenxbio | Formerly VC-backed | Rockville, MD | ||||
| NGM Biopharmaceuticals | Private Equity-Backed | South San Francisco, CA | ||||
| Renova Therapeutics | Venture Capital-Backed | Carlsbad, CA |
BridgeBio Pharma Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
BridgeBio Pharma Patents
BridgeBio Pharma Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| CA-3187759-A1 | Formulations of phosphoinositide 3-kinase inhibitors | Pending | 04-Aug-2020 | ||
| EP-4192431-A1 | Formulations of phosphoinositide 3-kinase inhibitors | Pending | 04-Aug-2020 | ||
| US-20220040193-A1 | Formulations of phosphoinositide 3-kinase inhibitors | Inactive | 04-Aug-2020 | ||
| JP-2025036464-A | Topical phosphoinositide 3-kinase inhibitor | Pending | 06-Feb-2019 | ||
| AU-2020219065-A1 | Topical phosphoinositide 3-kinase inhibitors | Pending | 06-Feb-2019 | C07D495/04 |
BridgeBio Pharma Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
BridgeBio Pharma Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
BridgeBio Pharma Investments & Acquisitions (13)
BridgeBio Pharma’s most recent deal was a Joint Venture with GondolaBio for . The deal was made on 16-Aug-2024.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| GondolaBio | 16-Aug-2024 | Joint Venture | Drug Discovery | ||
| Eidos Therapeutics | 26-Jan-2021 | Merger/Acquisition | Drug Discovery | ||
| Contour Therapeutics | 07-Dec-2020 | Joint Venture | Drug Discovery | ||
| Retinagenix Holdings | 01-Feb-2019 | Merger/Acquisition | Drug Discovery | ||
| Alexion (cyclic pyranopterin monophosphate) | 11-Jun-2018 | Corporate Asset Purchase | Buildings and Property |
BridgeBio Pharma ESG
Risk Overview
Risk Rating
Updated April, 26, 2025
35.24 | High Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
Management
Management is related to actions taken to manage ESG issues
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
of 14,697
Rank
Percentile
Pharmaceuticals
Industry
of 847
Rank
Percentile
Pharmaceuticals
Subindustry
of 420
Rank
Percentile
BridgeBio Pharma Exits (1)
BridgeBio Pharma’s most recent exit was on 01-Feb-2019 from Retinagenix Holdings. The exit was categorized as .
| Company Name | Exit Date | Exit Type | Exit Size | Status | Buyers |
|---|---|---|---|---|---|
| Retinagenix Holdings | 01-Feb-2019 | Completed |
|
BridgeBio Pharma Affiliates
Subsidiaries (1)
| Name | Industry | Location | Year Founded |
|---|---|---|---|
| BridgeBio Pharma (Rare Pediatric Disease Priority Review Voucher) | Palo Alto, CA |
BridgeBio Pharma FAQs
-
When was BridgeBio Pharma founded?
BridgeBio Pharma was founded in 2015.
-
Where is BridgeBio Pharma headquartered?
BridgeBio Pharma is headquartered in Palo Alto, CA.
-
What is the size of BridgeBio Pharma?
BridgeBio Pharma has 730 total employees.
-
What industry is BridgeBio Pharma in?
BridgeBio Pharma’s primary industry is Biotechnology.
-
Is BridgeBio Pharma a private or public company?
BridgeBio Pharma is a Public company.
-
What is BridgeBio Pharma’s stock symbol?
The ticker symbol for BridgeBio Pharma is BBIO.
-
What is the current stock price of BridgeBio Pharma?
As of 09-Jul-2025 the stock price of BridgeBio Pharma is $45.98.
-
What is the current market cap of BridgeBio Pharma?
The current market capitalization of BridgeBio Pharma is $8.73B.
-
What is BridgeBio Pharma’s current revenue?
The trailing twelve month revenue for BridgeBio Pharma is $127M.
-
Who are BridgeBio Pharma’s competitors?
IVERIC bio, Caribou Biosciences, Regenxbio, NGM Biopharmaceuticals, and Renova Therapeutics are some of the 94 competitors of BridgeBio Pharma.
-
What is BridgeBio Pharma’s annual earnings per share (EPS)?
BridgeBio Pharma’s EPS for 12 months was -$3.53.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read blog » -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process »
